Insulin Sensitivity of the Human CNS System: fMRI Study With Intranasal Insulin Application
- Registration Number
- NCT01797601
- Lead Sponsor
- University Hospital Tuebingen
- Brief Summary
The purpose of the study is to investigate whether insulin sensitivity and insulin resistance of the human brain is comparable in all insulin sensitive parts of the brain and whether correlates to other phenotypic information (i.e. whole body insulin sensitivity, BMI, age) of the study participants.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
- Normal routine blood works
- for women: negative pregnancy test
- healthy
Exclusion Criteria
- Type 2 diabetes
- pregnancy
- acute or chronic diseases
- Pacemakers
- Artificial heart valves
- Metal prostheses
- Implanted magnetic metal parts (screws, ...)
- Metal fragments
- Braces
- insulin pumps
- Tattoos
- claustrophobia
- reduced temperature sensation and / or increased sensitivity to warming of the body
- Ear disease or an increased sensitivity to loud noises
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Placebo solution Placebo Nasal spray Human Insulin Human Insulin Nasal spray
- Primary Outcome Measures
Name Time Method Insulin effect on regional brain activity assessed by fMRI Change from Baseline to 15 minutes and 60 minutes post spray application
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What neural pathways mediate intranasal insulin's effects on CNS insulin sensitivity in obesity and diabetes?
How does intranasal insulin compare to subcutaneous insulin in enhancing CNS insulin sensitivity in diabetic patients?
Which biomarkers correlate with CNS insulin resistance and whole-body metabolic parameters in NCT01797601 participants?
What adverse events were observed with intranasal insulin in CNS studies, and how do they compare to systemic hypoglycemia risks?
Are combination therapies involving intranasal insulin and CNS-targeted insulin receptor agonists being explored for metabolic disorders?
Trial Locations
- Locations (1)
University of Tuebingen
🇩🇪Tuebingen, Germany
University of Tuebingen🇩🇪Tuebingen, Germany